Sign inStart free

Health Care · Ophthalmic Goods

RXST RxSight, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 111148571 filings
Russell 2000
Follow RXST for alertsAsk AI about RXST

RXST at a glance

RxSight, Inc. (RXST, SEC CIK 1111485) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), RxSight, Inc. (RXST) reported revenue of $134.5 million (down 3.9% from FY2024) and a net loss of $38.9 million. Diluted EPS was -$0.95.
  • As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding RxSight, Inc. (RXST) shares worth $93.7 million in 13F-HR filings.
  • In the last 90 days, RXST insiders reported 0 open-market purchases ($0) and 4 open-market sales ($118K) on Form 4, a net sale of $118K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$134.5M
−3.9% vs prior year
Insiders · 90 days
0 buys · 4 sells
Net −$118K
13F holders
25 funds
$93.7M · −1 vs prior quarter
Latest 8-K
Aug 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Jun 30, 2026

Management Discussion & Analysis

  • No profitability or margin percentages provided in excerpt
  • Installed base 1,166 LDDs; approximately 357,000 LALs implanted through June 30, 2026
  • Expected continued net losses and negative operating cash flows in near term
  • July leadership transition, pipeline updates, and Alcon collaboration agreement; 3,500,000 shares reserved under inducement plan

Risk Factors

  • New Alcon collaboration risk triggered by June 2026 agreement, with $70 million feasibility and $40 million approval payments contingent on Alcon election
  • Most material commercial update: sales declined in 2025 and first-half 2026, prompting Customer Success Organization realignment
  • Legal risk: putative securities class action complaint filed July 2025 remains pending in the Central District of California
  • Competitive and operational risk: single-source suppliers expose RxSight system components to supply disruptions and price fluctuations
  • Liquidity risk: cash, cash equivalents and short-term investments declined to $208.8 million at June 30, 2026 from $228.1 million at December 31, 2025

AI summary of the RXST 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Aug 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for three months ended June 30, 2026
  • Press release issued August 5, 2026

Item EX-99.1: Item EX-99.1

  • Q2 revenue $33.7M, including $6.5M Alcon collaboration revenue; product sales fell 19% to $27.2M
  • Product gross margin declined to 71.2% from 74.9%; total margin reached 76.7% with collaboration revenue
Filed Jul 15, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Mottiwala appointed President and CEO, marking a leadership transition at RxSight
  • Dr. Kurtz transitioning to Chief Medical Officer, retaining a medical and clinical leadership role

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CEO transition effective July 20, 2026: Aziz Mottiwala replaces Ron Kurtz, who becomes Chief Medical Officer after leading since 2016
  • Mottiwala brings commercial leadership from Tarsus, Opiant, Avanir, and Allergan, potentially emphasizing commercialization execution

Item EX-99.1: Item EX-99.1

  • Leadership transition effective July 20, 2026, with Aziz Mottiwala becoming President and CEO
  • Ron Kurtz, M.D. moving to Chief Medical Officer, preserving founder-level product and clinical expertise
Filed Jul 6, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Alcon collaboration adds $60M upfront cash and potential $140M milestone payments tied to feasibility, FDA submission, and approval
  • 30% royalties on net Collaboration Product sales, with minimum royalty obligations and customary adjustments

Item 7.01: Regulation FD Disclosure

  • Forward-looking disclosure tied to RxSight-Alcon collaboration, including potential milestones and royalties
  • Payments remain contingent, with timing and realization uncertain

Item EX-99.1: Item EX-99.1

  • Non-exclusive Alcon collaboration expands RxSight’s light-adjustable technology into presbyopia-correcting lenses
  • $60 million upfront payment provides near-term development funding

AI summaries of RXST 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for RXST

Don't miss the next RXST filing

  • Alerts as it files. A push when RXST files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut RXST, by share count.
  • Ask anything. An AI agent that reads every RXST filing and answers with sources.
Follow RXST for alertsAsk AI about RXST
Compare plans →

RXST alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Weinberg EricMSep 15, 2026$4.34
Weinberg EricMSep 15, 2026-
Weinberg EricASep 5, 2026-
Weinberg EricDSep 5, 2026-
Weinberg EricDSep 5, 2026-
Weinberg EricDSep 5, 2026-
Weinberg EricDSep 5, 2026-
Wilterding MarkDSep 5, 2026-
Insider trades across all companies →Which insider buys matter →

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$139.9M$134.5M
Gross Profit-$98.9M$103.0M
Operating Income--$36.9M-$48.2M
Net Income--$27.5M-$38.9M
Gross Margin-70.7%76.6%
Op. Margin--26.3%-35.8%
Net Margin--19.6%-29.0%
Balance Sheet
Total Assets$182.6M$318.6M$311.8M
Equity$160.4M$281.2M$275.7M
ROE--9.8%-14.1%
Per Share
EPS-$-0.71$-0.95
Cash Flow
Operating CF--$16.9M-$15.5M
CapEx-$5.4M$3.8M

Source: XBRL data in RxSight, Inc. (RXST)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q2 2026

Aggregate RXST share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
RXST shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q2 202625$93.7M
Q1 202626$102.9M
Q4 202522$157.1M
Q3 202523$135.0M
Q2 202524$170.3M
Q1 202522$262.2M
Q4 202418$289.3M
Q3 202418$203.0M
Position changes: Q1 2026 → Q2 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 178 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

RXST filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Sep 16, 2026--
4Sep 9, 2026--
4Sep 9, 2026--
4Sep 9, 2026--
4Sep 9, 2026--
4Sep 2, 2026--
4Sep 2, 2026--
4Sep 2, 2026--
4Sep 2, 2026--
SC 13GAug 19, 2026-
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
4Jul 24, 2026--
SC 13GJul 17, 2026-
8-KJul 15, 2026Analysis-
8-KJul 6, 2026Analysis-
8-KJul 6, 2026Analysis-
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--

Related Health Care companies

All Health Care →

RXST SEC filings: frequently asked questions

Are RXST insiders buying or selling?

In the last 90 days, RxSight, Inc. (RXST) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $117,951 by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold RXST stock?

As of June 30, 2026, the largest RxSight, Inc. (RXST) holders among the 13F filers tracked by SignalX were BlackRock ($27.9 million), Millennium Management ($14.6 million), D.E. Shaw & Co ($9.6 million), Vanguard Capital Management LLC ($8.1 million), AQR Capital Management ($7.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was RXST's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), RxSight, Inc. (RXST) reported revenue of $134.5 million (down 3.9% from FY2024) and a net loss of $38.9 million. Diluted EPS was -$0.95. The figures come from the XBRL data in the 10-K.

What did RXST report in its latest 8-K?

RxSight, Inc. (RXST) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for three months ended June 30, 2026.

What are the latest RXST SEC filings?

RxSight, Inc. (RXST) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on September 16, 2026.

What is RXST's SEC CIK number?

RxSight, Inc. (RXST)'s SEC Central Index Key (CIK) is 1111485. EDGAR lists every RXST filing under that number.

Ask anything about RXST

The research agent reads RXST's filings, financials, insider trades and 13F holders, then answers with sources.

Start free